Jeffrey D. Isaacson

2.3k total citations
29 papers, 993 citations indexed

About

Jeffrey D. Isaacson is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jeffrey D. Isaacson has authored 29 papers receiving a total of 993 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jeffrey D. Isaacson's work include Prostate Cancer Treatment and Research (12 papers), Bone health and treatments (8 papers) and Radiopharmaceutical Chemistry and Applications (7 papers). Jeffrey D. Isaacson is often cited by papers focused on Prostate Cancer Treatment and Research (12 papers), Bone health and treatments (8 papers) and Radiopharmaceutical Chemistry and Applications (7 papers). Jeffrey D. Isaacson collaborates with scholars based in United States, United Kingdom and Germany. Jeffrey D. Isaacson's co-authors include Michael A. Carducci, Dale J. Kempf, Richard A. Rode, Martin King, Barry Bernstein, Eugene Sun, Darryl J. Sleep, Claude C. Schulman, David P. Dearnaley and Joel B. Nelson and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Journal of Virology.

In The Last Decade

Jeffrey D. Isaacson

29 papers receiving 953 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jeffrey D. Isaacson United States	11	407	388	343	286	169	29	993
Mark P. McLaughlin United States	15	228 0.6×	243 0.6×	183 0.5×	183 0.6×	110 0.7×	25	1.0k
Katherine L. Baker-Neblett United States	12	161 0.4×	581 1.5×	100 0.3×	328 1.1×	553 3.3×	17	1.4k
Emanuela Ricotti Italy	14	67 0.2×	98 0.3×	61 0.2×	116 0.4×	168 1.0×	22	681
S. Casanova Italy	16	56 0.1×	193 0.5×	16 0.0×	115 0.4×	224 1.3×	38	1.0k
Joseph W.Y. Lau Hong Kong	13	33 0.1×	118 0.3×	26 0.1×	189 0.7×	252 1.5×	31	860
Tsukasa Aihara Japan	15	53 0.1×	137 0.4×	12 0.0×	230 0.8×	329 1.9×	89	1.0k
Roshini Pradeep United States	10	115 0.3×	494 1.3×	4 0.0×	148 0.5×	189 1.1×	26	948
Connie Chan China	9	21 0.1×	238 0.6×	18 0.1×	284 1.0×	135 0.8×	15	814
Weijia Zhang United States	13	59 0.1×	28 0.1×	26 0.1×	58 0.2×	144 0.9×	26	655

Countries citing papers authored by Jeffrey D. Isaacson

Since Specialization

Citations

This map shows the geographic impact of Jeffrey D. Isaacson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey D. Isaacson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey D. Isaacson more than expected).

Fields of papers citing papers by Jeffrey D. Isaacson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey D. Isaacson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey D. Isaacson. The network helps show where Jeffrey D. Isaacson may publish in the future.

Co-authorship network of co-authors of Jeffrey D. Isaacson

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey D. Isaacson. A scholar is included among the top collaborators of Jeffrey D. Isaacson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey D. Isaacson. Jeffrey D. Isaacson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Goldman, Jonathan W., Jean‐Charles Soria, Heather A. Wakelee, et al.. (2016). Updated results from TIGER-X, a phase I/II open label study of rociletinib in patients (pts) with advanced, recurrent T790M-positive non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 34(15_suppl). 9045–9045. 9 indexed citations

Yang, James Chih‐Hsin, Sanjay Popat, Silvia Novello, et al.. (2016). TIGER-3: A phase 3 multinational open-label randomized study of rociletinib vs investigator-choice chemotherapy in patients (pts) with epidermal growth factor receptor mutant-positive (EGFRm) non-small cell lung cancer (NSCLC) progressing on prior EGFR tyrosine kinase inhibitor (TKI) therapy and doublet chemotherapy.. Journal of Clinical Oncology. 34(15_suppl). TPS9106–TPS9106. 2 indexed citations

Camidge, D. Ross, et al.. (2015). TIGER 1: A randomized, open-label, phase 2/3 study of rociletinib (CO-1686) or erlotinib as first-line treatment for EGFR-mutant non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 33(15_suppl). TPS8108–TPS8108. 4 indexed citations

Soria, Jean‐Charles, Filippo de Braud, Ratislav Bahleda, et al.. (2014). A phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors.. Journal of Clinical Oncology. 32(15_suppl). 2500–2500. 8 indexed citations

Kristeleit, Rebecca, Geoffrey I. Shapiro, Patricia LoRusso, et al.. (2013). A phase I dose-escalation and PK study of continuous oral rucaparib in patients with advanced solid tumors.. Journal of Clinical Oncology. 31(15_suppl). 2585–2585. 18 indexed citations

Ikdahl, Tone, Ірина Давиденко, Claudio Bassi, et al.. (2011). A multicenter, randomized, controlled study of CO-1.01 versus gemcitabine in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) and low tumor expression of human equilibrative nucleoside transporter-1 (hENT1) determined by metastasis biopsy.. Journal of Clinical Oncology. 29(15_suppl). TPS144–TPS144. 4 indexed citations

Carducci, Michael A., Fred Saad, Per‐Anders Abrahamsson, et al.. (2007). A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone‐refractory prostate cancer. Cancer. 110(9). 1959–1966. 236 indexed citations

Sleep, Darryl J., James B. Nelson, Daniel P. Petrylak, Jeffrey D. Isaacson, & Michael A. Carducci. (2006). Clinical benefit of atrasentan for men with metastatic hormone-refractory prostate cancer metastatic to bone. Journal of Clinical Oncology. 24(18_suppl). 4630–4630. 3 indexed citations

Vogelzang, Nicholas J., James B. Nelson, Claude C. Schulman, et al.. (2005). Meta-analysis of clinical trials of atrasentan 10 mg in metastatic hormone-refractory prostate cancer. Journal of Clinical Oncology. 23(16_suppl). 4563–4563. 38 indexed citations

10.

Yount, Susan, et al.. (2004). Impact of atrasentan on prostate-specific outcomes with hormone refractory prostate cancer patients. Journal of Clinical Oncology. 22(14_suppl). 4582–4582. 2 indexed citations

11.

Lipton, A., et al.. (2004). Benefit of Atrasentan in Men with Hormone Refractory Prostate Cancer Metastatic to Bone. Journal of Clinical Oncology. 22(14_suppl). 4687–4687. 3 indexed citations

12.

Mulani, Parvez, et al.. (2004). Relationship of bone alkaline phosphatase and quality of life in men with hormone refractory prostate cancer. Journal of Clinical Oncology. 22(14_suppl). 4688–4688. 1 indexed citations

13.

14.

Nelson, James B., et al.. (2004). Prostate-specific antigen doubling time as a predictor of prostate cancer disease progression and survival. Journal of Clinical Oncology. 22(14_suppl). 4554–4554. 2 indexed citations

15.

Schulman, C., et al.. (2004). 617 Atrasentan delays disease progression in men presenting with metastatic hormone refractory prostate cancer. European Urology Supplements. 3(2). 157–157. 1 indexed citations

16.

Carducci, Michael A., James B. Nelson, Fred Saad, et al.. (2004). Effects of atrasentan on disease progression and biological markers in men with metastatic hormone-refractory prostate cancer: Phase 3 study. Journal of Clinical Oncology. 22(14_suppl). 4508–4508. 43 indexed citations

17.

Zonnenberg, Bernard A., Gerard Groenewegen, Todd J. Janus, et al.. (2003). Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer.. PubMed. 9(8). 2965–72. 41 indexed citations

18.

Hsu, Ann, Jeffrey D. Isaacson, Scott Brun, et al.. (2002). Pharmacokinetic-Pharmacodynamic Analysis of Lopinavir-Ritonavir in Combination with Efavirenz and Two Nucleoside Reverse Transcriptase Inhibitors in Extensively Pretreated Human Immunodeficiency Virus-Infected Patients. Antimicrobial Agents and Chemotherapy. 47(1). 350–359. 125 indexed citations

19.

Kempf, Dale J., Jeffrey D. Isaacson, Martin King, et al.. (2002). Analysis of the Virological Response with Respect to Baseline Viral Phenotype and Genotype in Protease Inhibitor-Experienced HIV-1-Infected Patients Receiving Lopinavir/Ritonavir Therapy. Antiviral Therapy. 7(3). 165–174. 93 indexed citations

20.

Isaacson, Jeffrey D., et al.. (2000). Correlation between Human Immunodeficiency Virus Genotypic Resistance and Virologic Response in Patients Receiving Nelfinavir Monotherapy or Nelfinavir with Lamivudine and Zidovudine. The Journal of Infectious Diseases. 182(2). 420–427. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact